-
公开(公告)号:US20210069118A1
公开(公告)日:2021-03-11
申请号:US16753740
申请日:2018-10-08
申请人: Université De Bordeaux , Institut Polytechnique De Bordeaux , Centre National De La Recherche Scientifique , Fundación Cidetec
发明人: Sébastien LECOMMANDOUX , Damien DUPIN , Iraida LOINAZ BORDONABE , Hans-Jürgen GRANDE TELLERIA , Aitziber LOPEZ ELORZA , Elisabeth GARANGER
IPC分类号: A61K9/50 , A61K9/51 , A61K9/107 , B01J13/08 , A61K36/9066 , C08G81/00 , A61K31/164 , A61K31/23 , A61K31/728 , A61K31/704
摘要: The present invention relates to the use of a copolymer having the following formula (II): wherein: A1 is a linker, preferably an enzyme cleavable peptide sequence, and y is 0 or 1; AA is a residue of a hydrophobic amino acid; x is an integer comprised between 17 and 270; n is an integer comprised between 5 and 170; and m is an integer comprised between 0 and 80; optionally in the presence of a co-surfactant, as surfactant for the stabilization of an emulsion at a pH between 4 and 6.5.
-
公开(公告)号:US20210046046A1
公开(公告)日:2021-02-18
申请号:US17009586
申请日:2020-09-01
申请人: BioResponse, L.L.C.
发明人: Michael A. Zeligs , Irwin C. Jacobs
IPC分类号: A61K31/404 , A61K47/06 , A61K9/08 , A61K9/10 , A61K31/122 , A61K31/138 , A61K31/23 , A61K31/275 , A61K31/357 , A61K31/4045 , A61K31/59 , A61K9/48 , A61K9/127 , A61K47/00 , A61K9/00 , A61K9/14 , A61K31/215 , A61K47/10 , A61K47/24 , A61K47/26 , A61K47/38 , A61K47/46 , A61K9/107 , A61K45/06 , A61K47/14 , A61K47/34
摘要: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.
-
公开(公告)号:US20210045423A1
公开(公告)日:2021-02-18
申请号:US17021339
申请日:2020-09-15
申请人: Kate Farms, Inc.
发明人: Richard Laver , Michelle Laver , Brett Matthews , William Pickar , David Cole , Steven Witherly , Caroline Witherly , Vanessa Millovich , Christina Phreaner
IPC分类号: A23L33/18 , A23L33/105 , A23L33/12 , A23L33/16 , A23L33/15 , A23L33/21 , A61K31/353 , A61K31/216 , A61K31/375 , A61K31/7028 , A61K31/01 , A61K31/198 , A61K31/255 , A61K31/015 , A61K9/00 , A61K36/55 , A61K36/28 , A61K38/16 , A61K31/733 , A61K31/23 , A61K36/537 , A61K36/21 , A61K36/53 , A61K33/00 , A61K33/06 , A61K33/14 , A23L33/185
摘要: The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is a hydrolyzed pea protein based nutrient composition for use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein hydrolysates, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.
-
公开(公告)号:US20210038504A1
公开(公告)日:2021-02-11
申请号:US16986100
申请日:2020-08-05
摘要: A topical composition for treatment of a skin condition comprising a mixture of Leptospermum scoparium oil (manuka oil), Nigella sativa seed oil (black seed oil), and a carrier composition.
-
公开(公告)号:US10912755B2
公开(公告)日:2021-02-09
申请号:US16540747
申请日:2019-08-14
发明人: Roman Blaszczyk , Joanna Brzezinska , Anna Gzik , Adam A. Golebiowski , Julita Nowicka , Bartlomiej Borek , Marek Dziegielewski , Karol Jedrzejczak , Krzysztof Matyszewski , Jacek Olczak
IPC分类号: A61K31/69 , A61K31/343 , A61P11/00 , A61K31/23 , A61K31/235 , A61K31/133 , A61K31/335 , C07F5/02 , C07F5/04
摘要: Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.
-
公开(公告)号:US10882815B2
公开(公告)日:2021-01-05
申请号:US16127315
申请日:2018-09-11
发明人: Zheng Tao Han , Hung-Fong Chen
IPC分类号: A61K31/215 , A61K31/573 , A61K31/60 , C07C69/614 , A61K31/22 , A61K31/23 , A61K31/235 , A61K45/06 , C07C69/21 , C07C69/33 , C07C69/533 , C07C69/716 , C07C69/78 , A61K31/191 , A61K31/194 , A61K31/575
摘要: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
-
27.
公开(公告)号:US10828276B2
公开(公告)日:2020-11-10
申请号:US14646817
申请日:2013-11-26
申请人: APHIOS CORPORATION
IPC分类号: A61K31/203 , A61K31/352 , A61K31/07 , A61K31/22 , A61K31/23 , A61K31/365 , A61K9/51 , A61K9/48 , A61K9/00
摘要: Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.
-
28.
公开(公告)号:US20200330421A1
公开(公告)日:2020-10-22
申请号:US16886280
申请日:2020-05-28
发明人: Jae Wha Kim , Sei-Ryang Oh , Kyung Seop Ahn , Ho Bum Kang , Jae Min Shin , Young Eun Ko , Tae Suk Lee , Myung Hwan Kim , Jong Koo Kang , Yong-Hae Han , Ki Young Sohn
IPC分类号: A61K31/231 , A23L33/10 , A61K35/32 , A61K31/23
摘要: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
-
公开(公告)号:US20200316006A1
公开(公告)日:2020-10-08
申请号:US16786788
申请日:2020-02-10
发明人: Mehar Manku , Ian Osterloh , Pierre Wicker , Rene Braeckman , Paresh Soni , Joseph S. Zakrzewski
IPC分类号: A61K31/232 , A61K31/23
摘要: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
-
30.
公开(公告)号:US10786481B2
公开(公告)日:2020-09-29
申请号:US16069814
申请日:2017-02-22
申请人: Biomedical Analysis Center, Academy of Military Medical Sciences , Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences
发明人: Xuemin Zhang , Xinhua He , Tao Zhou , Zhenggang Liu , Tao Li
IPC分类号: A61K31/325 , A61K31/23 , A61K31/135 , C07C69/78 , C07C271/44 , C07C69/28 , C07D265/30 , C07C271/56 , A61K31/222 , C07C69/16 , A61P37/04 , A61P35/04 , A61K31/09
摘要: Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, wherein X is C═O or CH2; Y is NH, O or absent; R is a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T½=12˜24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoid environmental oxidation and increase the environmental stability of drugs containing the compounds.
-
-
-
-
-
-
-
-
-